Literature DB >> 20577824

Coagulation factor VIII levels are associated with long-term survival - interactions with gender in a large hospital-based cohort.

Florian M Kovar1, Claudia L Marsik, Christian Joukhadar, Thomas Perkmann, Helmuth Haslacher, Thomas Schickbauer, Paul A Kyrle, Oswald F Wagner, Georg Endler.   

Abstract

INTRODUCTION: Elevated coagulation factor VIII activity has been associated with increased risk for both venous and arterial thrombosis. The current study evaluated the influence of Factor VIII levels and interactions with gender on all cause mortality in a large Austrian cohort. PATIENTS AND METHODS: During 1991 and 2003, 11203 individuals, first ever request for laboratory analyses of FVIII: C, age > or =18 years, were included in this study. The median observation period was 5 years covering a total of 46000 person-years. The death rate was 17.1%.
RESULTS: Compared to individuals within the reference category (FVIII: C <94%) hazard ratios gradually increased from 1.4 (95% CI: 1.1-1.8) in the 152-170% category (5th decile) to finally 4.4 (95% CI: 3.5-5.5) in the >313% category (highest decile, all p < 0.05). The association between FVIII: C levels and mortality remained essentially unchanged when considering non-cancer mortality, all cause vascular mortality or mortality due to ischemic heart disease. Compared to males females with elevated FVIII: C had a worse outcome resulting in higher hazard ratios reaching 6.8 (95% CI: 4.6-9.9) within the highest decile compared to males (HR: 3.4 (95% CI: 2.6-4.5)).
CONCLUSIONS: In our large patient cohort we might be able to demonstrate for the first time that FVIII: C plasma activity is strongly associated with all cause mortality. Additionally, FVIII: C appears to interact with gender. Especially in women FVIII: C might help identifying high-risk cohorts, which might benefit from individualized prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577824     DOI: 10.1007/s00508-010-1386-1

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  27 in total

1.  Genetic determinants of hemostasis phenotypes in Spanish families.

Authors:  J C Souto; L Almasy; M Borrell; M Garí; E Martínez; J Mateo; W H Stone; J Blangero; J Fontcuberta
Journal:  Circulation       Date:  2000-04-04       Impact factor: 29.690

2.  FVIII coagulant activity and antigen in subjects with ischaemic heart disease.

Authors:  G I Rice; P J Grant
Journal:  Thromb Haemost       Date:  1998-11       Impact factor: 5.249

3.  High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene.

Authors:  P W Kamphuisen; J C Eikenboom; F R Rosendaal; T Koster; A D Blann; H L Vos; R M Bertina
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

4.  Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions.

Authors:  P W Kamphuisen; J C Eikenboom; H L Vos; R Pablo; A Sturk; R M Bertina; F R Rosendaal
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

Review 5.  von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis.

Authors:  Ida Martinelli
Journal:  Semin Hematol       Date:  2005-01       Impact factor: 3.851

6.  Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response.

Authors:  J O'Donnell; A D Mumford; R A Manning; M Laffan
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

Review 7.  The relationship between ABO histo-blood group, factor VIII and von Willebrand factor.

Authors:  J O'Donnell; M A Laffan
Journal:  Transfus Med       Date:  2001-08       Impact factor: 2.019

Review 8.  Elevated clotting factor levels and venous thrombosis.

Authors:  Rogier M Bertina
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Sep-2004 Dec

Review 9.  The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism.

Authors:  Paul Alexander Kyrle; Sabine Eichinger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

10.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more
  2 in total

1.  Factor VIII concentration is greater in female than male patients with HIV infection.

Authors:  Alireza Abdollahi; Afsaneh Morteza; Omid Khalilzadeh; Ahmad Ahmadzadeh
Journal:  Int J Hematol       Date:  2010-12-15       Impact factor: 2.490

2.  Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.

Authors:  Chiara Mandoj; Laura Pizzuti; Domenico Sergi; Isabella Sperduti; Marco Mazzotta; Luigi Di Lauro; Antonella Amodio; Silvia Carpano; Anna Di Benedetto; Claudio Botti; Francesca Ferranti; Anna Antenucci; Maria Gabriella D'Alessandro; Paolo Marchetti; Silverio Tomao; Giuseppe Sanguineti; Antonio Giordano; Marcello Maugeri-Saccà; Gennaro Ciliberto; Laura Conti; Patrizia Vici; Maddalena Barba
Journal:  J Transl Med       Date:  2018-05-16       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.